相关实验视频

Updated: Jul 12, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

在乳腺癌中CDK4/6治疗下体外微RNA表达特征的改变

Jasmin Asberger^1,2, Kai Berner^1,2, Anna Bicker^1,2,3

¹Department of Obstetrics and Gynecology, Medical Center-University Hospital Freiburg, 79106 Freiburg, Germany.

|October 28, 2023

概括

微RNA可以预测乳腺癌治疗反应. 细胞外微RNAs miR-100,miR-10b和miR-182在循环素依赖激酶 (CDK) 抑制下显示为治疗反应的循环生物标志物.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物标志物发现发现

背景情况:

乳腺癌是全球领先的癌症,循环林依赖激酶 (CDK) 抑制剂是转移性治疗的基石.
治疗失败是常见的,需要新的策略来预测治疗反应.
微RNAs (miRNAs) 正在作为治疗疗效的潜在生物标志物进行研究.

研究的目的:

评估特定微RNAs (miRNAs) 的生物标志物潜力,以预测乳腺癌治疗反应.
在palbociclib和letrozole治疗下分析miRNA表达变化.

主要方法:

对56种miRNA的细胞内和细胞外miRNA表达水平的分析.
在乳腺癌细胞系 (BT-474,MCF-7,HS-578T) 上利用定量聚合酶链反应 (qPCR).
在palbociclib单一治疗和与莱特醇联合治疗下研究的miRNA变化.

主要成果:

一个独特的palbociclib诱导的miRNA签名被确定在细胞内和细胞外.
细胞内miRNAs (miR-10a,miR-15b,miR-21,miR-23a,miR-23c) 在细胞系中显示出一致的调节.
细胞外的miRNAs (miR-100,miR-10b,miR-182) 得到了一致的调节,miR-17在激素受体阳性细胞中显示出特定的调节.

结论:

细胞外miRNAsmiR-100,miR-10b和miR-182是有希望的循环生物标志物,可以预测由于它们的分泌和上调,对CDK抑制剂的治疗反应.
细胞内miRNAsmiR-10a,miR-15b,miR-21,miR-23a和miR-23c代表了评估治疗反应的潜在基于组织的生物标志物.

关键词:

这是一种CDK抑制剂.乳腺癌乳腺癌乳腺癌循环中的微RNAs.疾病生物标志物疾病生物标志物微RNAs 是一个微型RNA.这是palbocicliblib.治疗反应治疗反应的治疗.尿路中的微RNAs.

更多相关视频

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...